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Abstract
Objective: To explore the cumulative genotoxic damage to glioblastoma (GBM) cells, 
grown as multicellular spheroids, following exposure to 6 MV X-rays (2 Gy, 22 Gy) with or 
without, 2- methoxy estradiol (2ME2), iododeoxyuridine (IUDR) or topotecan (TPT), using 
the Picogreen assay.   
Materials and Methods: The U87MG cells cultured as spheroids were treated with 6 
MV X-ray using linear accelerator. Specimens were divided into five groups and ir-
radiated using X-ray giving the dose of 2 Gy after sequentially incubated with one of 
the following three drug combinations: TPT, 2-ME2/TPT, IUDR/TPT or 2ME2/IUDR/
TPT. One specimen was used as the irradiated only sample (R).  The last group was 
also irradiated with total dose of 22 Gy (each time 2 Gy) of 6 MV X-ray in 11 fractions 
and treated for three times. DNA damage was evaluated using the Picogreen method 
in the experimental study.    
Results: R/TPT treated group had more DNA damage [double strand break (DSB)/sin-
gle strand break (SSB)] compared with the untreated group (P<0.05).  Moreover the R/
TPT group treated with 2ME2 followed by IUDR had maximum DNA damage in spheroid 
GBM indicating an augmented genotoxicity in the cells. The DNA damage was induced 
after seven fractionated irradiation and two sequential treatments with 2ME2/IUDR/TPT. 
To ensure accuracy of the slope of dose response curve the fractionated radiation was 
calculated as 7.36 Gy with respect to α/β ratio based on biologically effective dose (BED) 
formulae.                 
Conclusion: Cells treated with 2ME2/IUDR showed more sensitivity to radiation and 
accumulative DNA damage. DNA damage was significantly increased when GBM 
cells treated with TPT ceased at S phase due to the inhibition of topoisomerase 
enzyme and phosphorylation of Chk1 enzyme. These results suggest that R/TPT-
treated cells increase sensitivity to 2ME2 and IUDR especially when they are used 
together. Therefore, due to an increase in the level of DNA damage (SSB vs. DSB) 
and impairment of DNA repair machinery, more cell death will occur. This in turn may 
improve the treatment of GBM.  
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Introduction
One of the most prevalent and deadly tumors 
of the brain is glioblastoma (GBM) multiforme. 
Its prevalence is mostly found in people of 45 to 
65 years of age. It is considered to be among the 
primary tumors of the central nervous system and 
is more common among Americans and Africans 
with male to female ratio of 3:2 and incidence rate 
of ≈ 5/100000 (1, 2).
Lack of an effective treatment has diminished hope 
for the survival of patients from this deadly tumor. 
To treat the tumor various methods such as surgery, 
radiotherapy, chemotherapy and radio-chemotherapy 
have been used but the results have not been satisfac-
tory yet (3). For instance, chemotherapy is often toxic 
to bone marrow and radiotherapy, delivered by exter-
nal beam, has also been shown to be toxic to normal 
brain tissues and the marrow. In radiotherapy, the dose 
which can be administered is severely limited by its 
ill-effects in normal tissue. Thus use of an appropriate 
dose to preserve the viability of bone marrow tissue 
is very crucial, hence radiotherapy alone has not been 
very effective (2). Chemotherapy is employed to de-
stroy cancerous cells, however, to the level that toxic-
ity of drug would be tolerated by normal tissues (4). 
Therefore, new methods should be explored to pro-
duce safe and effective results. The use of radiosen-
sitizers like 2-methoxy estradiol/iododeoxyuridine/
topotecan (2ME2/IUDR/TPT) combined with frac-
tional radiotherapy is among the important techniques 
for achieving this goal all of which were employed 
concurrently in this study.
TPT derived from the Chinese tree Camptotheca 
acuminata with the commercial name Hycamtin 
is a radiosensitizer agent and used recently as a 
chemotherapeutic drug (5, 6). This compound is 
used in a vast array of cancers such as ovarian can-
cer, lung cancer, leukemia, non-Hodgkin’s lym-
phoma, myelodysplastic syndrome, melanoma, 
colorectal and has been recently tested on GBM 
on both children and adults (6, 7).
TPT stops the cell cycle through inhibition of 
topoisomerase I (Topo-I) enzyme activity. Inhibi-
tion of this enzyme will lead to phosphorylation 
of DNA which in turn increases both DNA-Topo 
I complexes and double strand breaks (DSB), and 
finally leads to apoptotic death (3, 6 , 8).
The reduction of Topo-I, due to the activity of P53 
protein in wild-type (U87) cells, is seen 2 hours af-
ter the start of TPT treatment (6). An in vivo study 
showed that in radio-chemotherapy best results could 
be achieved when TPT is injected 2-4 hours prior to 
radiation. On the other hand, injection 2 hours after 
the radiation did not produce a noticeable effect (8). 
The Canadian National Cancer Society has evaluated 
TPT toxicity in a large group of patients and deter-
mined the tolerable dose of 2.3 mg/m2 (5 µM) for less 
than 3 days and 0.5 mg/m2 (1.1 µM) for a one-month-
long treatment (5 days a week) (9). Tomicic et al. (6) 
also applied identical TPT concentration of 1-4 µg/ml 
for short exposure periods (up to 24 hours) in GBM 
cells. In U87 glioma cells, 1 µM concentration of TPT 
can cause phosphorylation of P53, which leads to sen-
sitivity of TPT (10). Combination of TPT with [131I] 
meta-iodobenzylguanidine ([131I] MIBG) has been 
useful in treating neuroblastoma in vitro and in vivo 
and addition of TPT simultaneously or after addition 
of [131I] MIBG can increase the cell uptake of TPT (3).
TPT liposome with tamoxifen and wheat germ 
agglutinin will increase the transfer rate of the 
drug from the blood-brain barrier and penetration 
in tumor, and result in reduction of tumor volume 
and hence more benefit in the treatment. This ex-
periment has been carried out as in vitro-in vivo 
in glioma cells of the brain (11, 12). In order to 
increase the survival period of GBM patients, re-
search has shown that combining radiotherapy 
with TPT could result in an increase of 1-2 years 
in survival rate which is a 16% increase (7).
 IUDR was used as a radiosensitizer early 1960s 
and has replaced thymidine for DNA replication 
and in reaction with hydrated electrons infused by 
ionized rays, produces reacting uracil free radicals 
and halide ions, and finally causes single strand 
break and subsequently DSB in DNA thus causing 
cellular death (13, 14).
 Hypoxia inducible factors (HIF-1a) is a heterodi-
mer transcription factor responsible for stopping cell 
cycles in endothelial cells at G0/G1 phases; its activ-
ity is inhibited by methoxy estradiol and this in turn 
leads to inhibition of cell cycle checkpoints. Experi-
ments have shown that damages caused by ionizing 
irradiation following sensitization by IUDR in sphe-
roids cells treated with 2ME2 is far more effective 
than employing IUDR alone (13, 15).
Six MV X-ray was used in this research. One of 
the reasons for using this kind of ray was the abil-
ity to control the output. With the collimation sys-
tem, excess radiation can be controlled for healthy 
tissues surrounding the tumor and dose optimiza-
tion can be improved (16).
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In this study TPT was used along with IUDR and 
2ME2 as radiosensitizer agents to explore their 
combination for a possible cumulative effect and 
improvement in tumor treatment.
Three-dimensional culture systems are closer 
to tumor behavior and consist of three layers of 
anoxia, hypoxia and normoxia. The use of these 
multicellular spheroid models will also reduce the 
need for whole-animal studies in order to mimick 
small tumors and micrometastases (17).
We used the Picogreen method as a suitable tool 
to determine the single strand break (SSB)/DSB ra-
tio and as a sensitive probe for determing the level 
of damage to DSB. Its advantages include the fol-
lowing: i. it was an easy and fast method, ii. required 
only a few samples , iii. a sensitive method with high 
accuracy, iv. it had a vast range of manifestation, v. 
it did not become imbalanced because of cell metabo-
lism due to nano-matter, vi. strong signal to nuance 
and vii. it can be applied to frozen samples (18, 19). 
Cells cultures were stained through Picogreen which 
acted as a fluorescent color. The Picogreen binds to 
DNA threads with DSB breaks and when we dena-
tured DNA by alkaline buffer, the free Picogreen in a 
given time was equivalent to SSB and DSB in DNA. 
To quantify the results obtained from DNA damages, 
we used plasmid emancipated from bacteria, in the 
manner that all DNA threads were destroyed by the 
DNase enzyme (20, 21). We then added Picogreen 
and measured fluorescence intensity. Despite the re-
search done on the effect of TPT on cancer cells of 
different organs, little information is available regard-
ing the mechanism of changes in cell nuclei. On the 
other hand, research has shown that DNA as a target 
molecule plays an important role in the process of cel-
lular damage.
Materials and Methods
Cell line 
In the experimental study, human GBM cell line 
U87MG was purchased from the Pasteur Institute 
of Iran and cultured in minimum essential medium 
(MEM, Gibco/Invitrogen, USA) supplemented with 
10% fetal bovine serum (FBS, PAA/Austria), 100 U/
ml of penicillin streptomycin (PAA/ Austria) and 20 
U/ml of fungizone (Gibco/Invitrogen, USA). 
Spheroid culture
Spheroids were cultured using the liquid overlay 
technique. A total 5×105 cells were seeded in 100 
mm T-25 flasks (NEST/Austria) coated with a thin 
layer of 1% agar (Sigma/Aldrich, Germany) with 
10 ml of MEM supplemented with 10% FBS. The 
plates were incubated at 37˚C in a humidified att-
mosphere and 5% CO2 (memmert, Germany). Half 
of the culture medium was replaced with fresh cul-
ture medium every three days to feed the cells.
Growth curve
To draw spheroid growth curve, one spheroid 
cell was seeded per well in multi-well plates coat-
ed with a thin layer of 1% agar and 1 ml of MEM. 
The multi-well plate was incubated at 37˚C in a 
humidified atmosphere and 5% CO2. For 28 days, 
at 72 hours intervals, the vertical diameters of cells 
from triplicate were measured by a microscope. 
Next, cell volumes were calculated according to 
the formula V=a.b2.π/6 where a is the small diam-
eter of the cells, b is the large diameter of the cells 
and V is the volume of spheroid cells. An average 
of nine counts was used to define each point [mean 
± standard error mean (SEM)]. Half of the culture 
medium was replaced with fresh medium twice 
per week. Then the growth curve was plotted. In 
the linear area or logarithmic phase of the curve, 
the cell volume follows the formula V=V
0
×ekt 
where V
0
 is the initial volume of the cells, V is the 
volume of the cells after time t and k is the gradient 
of the logarithmic phase of the curve. The volume 
doubling time (VDT) of the cells was then deter-
mined according to the gradient of the logarithmic 
phase of the curve.
Drug treatment and cell irradiation by 6 MV 
X-ray linac
Glioma cancer cells were grown on a layer as 3 
dimensional spheroid cells in a liquid media with 
300 μm diameters. Then irradiated cells with X-
ray were treated with three types of drugs includ-
ing: 2ME2, IUDR and TPT.
In this study, 6 groups of growth cultures were 
set-up:
1. Control group 
2. Group not treated (this sample was irradiated)
3. Group treated with TPT
4. Group treated with 2ME2/TPT
5. Group treated with IUDR/TPT                                         
6. Group treated with 2ME2/IUDR/TPT 
Groups 2-5 were irradiated once with 2 Gy dose 
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of 6 MV X-ray. Group 6 was treated sequentially 
with 2- 2ME2 for 1 VDT, IUDR for 1 VDT TPT 
for 2 hours, then one flask was irradiated once with 
a 2 Gy dose of 6 MV X-ray and eleven flasks were 
treated for three times during this period and ir-
radiated with total of 22 Gy dose (each time 2 Gy) 
of 6 MV X-ray in 11 fractions. The concentration 
of drugs were 250 µM, 1 µM and 1 µg/ml, respec-
tively in MEM containing 10% FBS (22, 10). At 
the end of the exposure, the DNA damage was 
evaluated using the Picogreen method.
Picogreen assay
Radiation-induced SSB and DSB in the DNA of 
GBM cells were evaluated using the Picogreen as-
say according to the protocol by Schroder et al. 
(23). The solution used to denature  DNA was pre-
pared as follows:
Fluorescent dye stock solution was the Picogreen ds-
DNA quantitation reagent (solution A, Life Technol-
ogy/Invitrogen, USA). Calcium and magnesium-free 
phosphate buffered saline (PBS, Ca/Mg-free PBS) 
consisted of 137 mM Nacl, 2.7 mM KCL, 4.3 mM 
Na2HPO4 and 1.5 mM KH2PO4 (solution  B, Gibco/
Invitrogen, USA). The lysing solution contained 9.0 
M urea, 0.1 % sodium dodecyl sulfate (SDS) and 
0.2 M ethylene diaminetetraaceticacid (EDTA) at 
pH=10 with NaOH (solution C, Sigma/Aldrich, Ger-
many). Lysing solution supplemented with Picogreen 
consisted of 10 μL of the original stock dye/ml of 
solution C (solution D, Life Technology/Invitrogen, 
USA). The EDTA solution contained 20 mM EDTA 
(solution E, Sigma/Aldrich, Germany). NaOH stock 
solution consisted of 1.0 M NaOH and 20 mM EDTA 
(solution F, Gibco/Invitrogen, USA). Working NaOH 
solution was prepared fresh prior to use. A total of 2 
mL of solution F was added to 18 mL of solution E 
with pH at 12.40 ± 0.02 to create solution G.
In order to determine the DSB induced in GBM 
cells, 3 tubes with 50,000 cells/mL for each group 
were prepared with 300 µl of solution C and 300 µl 
of solution D. To lyse the cells, all cell groups were 
placed in the dark for 40 minutes. The amount of DSB 
were determined by measuring fluorescence intensity 
for each cell group with a spectroflourometer (Shi-
madzu/USA) at 485 nm excitation and 528 nm emis-
sion wavelengths.
Next, 50 μl of solution G was added to 600 μl of 
lysed cells in each group (control, irradiated and 
treated+irradiated). The amount of SSB was deter-
mined after three hours by measuring fluorescence 
intensity in each group. 
Preparing the calibration curve
To determine the amount of fluorescence inten-
sity for digestion of all DNA in cells, various con-
centrations of DNase combined with 300 μl of so-
lution D and variable volume of PBS (resulting in 
the final volume of 800 µL) were added to various 
concentrations of  non-irradiated intact GBM and 
lysed cells (50,000 cells/ml solution C).
Statistical analysis
Statistical analysis was performed using inde-
pendent-samples t test and ANOVA followed by 
scheffe test as the post-hoc analysis by SPSS soft-
ware version 16. P<0.05 was considered to be sig-
nificant.
Results
Spheroid culture
U87MG cells were turned into spheroids in liq-
uid overlay cultures. The VDT of these spheroids 
was approximately 58.77 hours which was applied 
as the drug treatment time for cells (Fig.1).
Fig.1: Growth curve of U87MG cell line in spheroid cultures. An 
average of nine counts was used to define each point. Mean ± 
SEM of three experiments is shown on the curve.
y; Volume (µm3), x; Time (day), R2; Regression coefficient and 
SEM; Standard error mean.
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Double strand break and single strand break in 
DNA molecules                                                                                                     
The Picogreen assay was used to determine the 
prescence of induced SSB and DSB in DNA. The 
spectrum obtained at 300 µm   from samples of the 
irradiated ,treated and control groups of  U87MG 
cells, and spheroids treated with Picogreen solu-
tion were measured at an excitation wavelength 
of 485 nm and emission wavelength  of 530 nm 
(taken by a Shimadzu spectroflourometer). The 
average fluorescence intensity in the control and 
treated  groups for GBM cells with 2 Gy and 
total dose of 22 Gy (each time 2 Gy) of 6 MV X-
ray in presence of 2ME2, IUDR TPT are shown 
in tables 1 and 2. Table 1 shows fluorescence 
reduction in the treated and irradiated groups. 
Whenever radiation and treatment processes had 
to be repeated, on one hand we observed an in-
crease in DSB and on the other hand a reduction 
in SSB in DNA (Table 2).
Table 1: Measured average fluorescence intensity of control GBM cells and those irradiated by 2 Gy 
X-ray 6 MV, to determine the amount of SSBs and DSBs in presence of 2ME2, IUDR and TPT  
Mean  fluorescence nm (SSB)Mean fluorescence nm (DSB)Group
496.64 ± 10.04595.72 ± 14.38Control
455.84 ± 7.48514.12 ± 14.28R
442.24 ± 7.48485.22 ± 3.74R+TPT
429.66 ± 8.10 496.92 ± 7.48 R+2ME2+TPT
411.64 ± 7.48456.32 ± 7.48R+IUDR+TPT
388.52 ± 6.80437.52 ± 10.88R+2ME2+IUDR+TPT
GBM; Glioblastoma, SSB; Single strand break, DSB; Double strand break, 2ME2; 2-Methoxy estradiol, 
IUDR; Iododeoxyuridine, TPT; Topotecan and R; Radiation.
Table 2: The measured average fluorescence intensity of irradiated GBM cells by total does of 22 Gy (2Gy/fraction) with 6 MV X-ray in 
presence of 2ME2, IUDR and TPT (thrice) , to determine the amount of SSB and DSB 
8-117654321Fraction
16-221412108642Total dose (Gy)
257.16 ± 12.07257.00 ± 9.18  270.34 ± 12.24318.96 ± 10.54357.72 ± 14.28389.00 ± 8.50416.54 ± 9.86   437.52 ± 10.88  Mean fluorescence
(nm, DSB)
496.16 ± 6.18496.64 ± 6.80493.92 ± 6.80480.32 ± 6.46455.84 ± 15.30431.30 ± 9.52408.24 ± 10.71388.52 ± 6.80Mean fluorescence
(nm, SSB)
GBM; Glioblastoma, SSB; Single strand break, DSB; Double strand break, 2ME2; 2-Methoxy estradiol, IUDR; Iododeoxyuridine and TPT; 
Topotecan.
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To determine the percent of induced SSB and 
DSB in DNA, a calibration curve was drawn. To 
plot the curve, the average amount of fluorescence 
intensity was calculated from control and DNase 
treated groups. The average fluorescence intensity 
in control group in comparison with treated groups 
was significantly different (P<0.05). Decrease in 
fluorescence intensity indicated variation in DNA 
breaks. Gradient of the linear phase of the curve 
showed 1% break in DNA. The difference of in-
tensity per break in the DNA strand was equiva-
lents to 341.5, which means, for every 3.415≈3.4 
changes in amount of fluorescence intensity, a 
1% break occurs. The plotted calibration curve is 
shown in figure 2. 
Fig.2: Calibration curve obtained by the amount of fluorescence 
intensities of control group and DNase- treated group.  3.4 fold 
change in amount of fluorescence intensity indicates 1% break 
in DNA.
y; Average fluorescence intensity, x; Percent of digestion  DNA 
and R2; Regression coefficient.
The difference between average intensities 
in the control and treated groups was 3.4-fold. 
Figure 3 display the distribution of the percent-
age of SSB and DSB in DNA. Combination of 
R/TPT increased the DSB and SSB in compari-
son with the group of R (P<0.05). Moreover, 
successive treatment of cells with R/2ME2/TPT 
can significantly increase the DSB and SSB 
when compared with the R group (P<0.05). The 
comparison of combination of treated cell with 
R/IUDR/TPT and the R group alone is shown 
in figure 3. Furthermore, DSB and SSB signif-
icantly increased in the presence of TPT with 
irradiation of X-6 MV after incubation with 
2ME2+IUDR when compared with the other four 
groups R, R/TPT, R/TPT/2ME2 and R/IUDR/
TPT  (P<0.05). Table 3, shows an increase in 
DNA damage percentage of 300 μm spheroids in 
the three groups of R/TPT/2ME2, R/TPT/IUDR 
and R/TPT /2ME2/IUDR in comparison with the 
R/TPT group. The effect of combined treatment 
with R/TPT/2ME2/IUDR was greater than the 
sum of the effects in two groups of stradiol R/
TPT/2ME2 or R/TPT/IUDR.
In figure 4, successive double treatment of 
cells with 2ME2/IUDR/TPT and fractional ra-
diation with total dose of 14 Gy (2 Gy/fraction) 
by 6 MV X-ray can significantly increase the 
DNA damage in comparison with single treat-
ment and irradiated groups (P<0.05). In the 
other words, by repeating irradiation from 1 to 
7 fractions and repeating drug treatment twice, 
SSB was reduced while we observed an in-
crease in DSB in DNA. In other words, the SSB 
converted to the DSB in fractional radiotherapy 
with X-ray.
Fig.3: Distribution of   average percentage of SSB and DSB in GBM 
cell groups irradiated (2Gy) and treated with 2ME2/IUDR/TPT. 
SSB; Single strand break, DSB; Double strand break, GBM; Glio-
blastoma, 2ME2; 2-Methoxy estradiol, IUDR; Iododeoxyuridine, 
TPT; Topotecan and R; Radiation.
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Table 3: An increase in DNA damage percentage of 300 µm spheroids in three groups of 2ME2/R/TPT, IUDR/R/TPT and 2ME2/IUDR/R/
TPT in comparison with the R/TPT group
Increase in DNA damage  percentage 
in group of 2ME2/IUDR/R/TPT in 
comparison with R/TPT
Increase in DNA damage  percentage 
in group of IUDR/R/TPT in 
comparison with R/TPT
Increase in DNA damage  percentage 
in group of 2ME2/R/TPT in 
comparison with R/TPT
29.83%17.50%8.20%
2ME2; 2-Methoxy estradiol, IUDR; Iododeoxyuridine, TPT; Topotecan and R; Radiation.
The total DNA damage dose-effect  relation-
ship  was  found  to  be  linear  in  the radiation 
treatment group with fraction range of 1 to 7 (2 
Gy/fraction). Moreover intensity of the damage 
in the seventh fraction of irradiation reached the 
ultimate limit (%100). DNA damage was sig-
nificantly different in all treated and irradiated 
groups before the sixth fraction when compared 
with treated and irradiated group at the sixth 
fraction (P<0.05). We used the biologically ef-
fective dose (BED) formulae to determine the 
α/β ratio of 2 Gy in alternative fractions (Fig.5). 
The α/β ratio calculated by equation BED50% 
was 7.36 Gy.
Fig.4: Distribution of average percentage of SSB and DSB of GBM 
cells in the irradiated [(22Gy (2Gy/fraction)] and the treated 
groups with 2ME2/IUDR/TPT (twice). 
SSB; Single strand break, DSB; Double strand break, GBM; Glioblas-
toma, 2ME2; 2-Methoxy estradiol, IUDR; Iododeoxyuridine and TPT; 
Topotecan. 
Fig.5: Dose-response effects of X-ray on DNA damage assessed by 
the Picogreen in the irradiated [14Gy (2Gy/fraction)] and treated 
groups with 2ME2/IUDR/TPT (twice). An average of nine counts 
was used to define each point. Mean ± SEM of three experiments is 
shown on the curve.
2ME2; 2-Methoxy estradiol, IUDR; Iododeoxyuridine, TPT; To-
potecan and SEM; Standard error of mean.
Discussion
IUDR as a radiosensitizer is more absorbed by 
cancer cells with high level of proliferation op-
posed to healthy tissues with low rate of cell di-
vision (12). As the absorption of IUDR increases, 
the level of single and double breaks increases. 
Therefore, the best choice for assessing these sen-
sitizers is cancer cells with high cell division rate 
which are surrounded by healthy indivisible cells. 
Thus glioma are considered to be the best choice 
since these tumor cells are surrounded by healthy 
nerve cells with no ability to divide (13). 2ME2 
is a potential therapeutic agent for multiple types 
of tumor including GBM (24-26). It leads to the 
inhibition of the cell cycle checkpoints in G0/G1 
phases (24). Experiments have shown that dam-
ages caused by ionizing irradiation after incuba-
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tion with 2ME2 and IUDR  in spheroids treated 
with 2ME2 is far more than employing IUDR 
alone (27, 28). Moreover, 2ME2 causes interrup-
tion in cell cycle in G2/M phases by affecting mi-
crotubules and prevents cancer proliferation. Thus, 
2ME2 caused increase in DNA damage as a radio-
sensitizer (29). In prior studies, 2ME2 was shown 
to block the growth of colon carcinoma cells and 
to induce apoptosis (30). In another study, 2ME2, 
as a potential cytostatic drug, increased autophagic 
cell death in glioma cells (29). TPT is a radiosen-
sitizer and more recently has been studied in vitro 
and in vivo as a chemotherapeutic drug (7, 31, 32).
The Topo-I inhibitor in TPT is a nuclear enzyme 
that plays a crucial role in DNA replication and in 
transcription (33). A recent study has shown that 
nano-liposomal topotecan increased DNA strand 
breaks and the activity of caspase-3 (marker of 
programmed cell death) by convection-enhanced 
in brain tumors (34). In another study genstein and 
TPT induced cellular death in LNCap cells (pros-
tate cancer) by inhibiting topo- I, II enzyme (35).
In this study TPT was widely used along with 
other radiosensitizer like 2ME2 and IUDR. Our 
previous study show that combination of ioniz-
ing radiation and TPT could cause synergistic cell 
killing in various human cancer cells even  from 
highly radioresistant tumors (31). The goal of ra-
diotherapy treatment is to irradiate the tumoral 
lesion while minimizing the undesirable effects 
on the neighboring tissues. One of the techniques 
based on this notion is the technique of fractional 
radiotherapy. In this method, the carcinogenic cell 
cannot revive as quickly as the normal cells (36). 
The processes have been described by the four Rs 
of radiobiology: as repair, re-distribution in the 
cell cycle, re-population and re-oxygenation (37). 
Repair and re-population spare normal tissues in 
the fractional radiotherapy whereas re-oxygena-
tion and re-assotment increase damages to tumor 
(38). Therefore this method could be effective in 
tumor treatment. Combs et al. (39) reported that 
fractionated radiation with X-rays and carbon ions 
enhanced the lethal effects of radiation in GBM.
Our results revealed that combination of 
R/2ME2/IUDR/TPT could significantly increase 
DSB and SSB in DNA molecules compared with 
the four groups R, R/TPT, R/TPT/2ME2 or R/
IUDR/TPT.
IUDR at the time of cell cycle’s synthesis stage 
replaces thymidine in DNA threads and increases 
damage and cell destruction (13). 2ME2 prevent-
ed cells from entering the G0 phase, increased 
IUDR uptake and also caused more sensitivity to 
radiation treatment (24, 28). Finally by employ-
ing TPT, with the capability to inhibit topo-I en-
zyme, higher level of DNA damage was induced 
by radiation with X-ray after incubation with 
2ME2 and IUDR (33). With fractionated irradia-
tion from 1 to 7 fractions and double drug treat-
ment, SSB was converted to DSB. Zhang et al. 
(40) reported that TPT combined with chrono-
radiotherapy could enhance the radiosensitivity 
of human nasopharyngeal carcinoma. Khoei et 
al. (28) reported that increase of incubation time 
from 1 to 2- VDT in 2ME2 treated spheroids pro-
duced DNA damage in the cells. Fractionated 
radiation therapy is an important way of achiev-
ing more severe cellular damage due to increas-
ing DSB and complex damage in DNA.  Dose-
response effects of R/2ME2/IUDR/TPT on GBM 
damage were assessed by the Picogreen assay in 
7 fractions (2 Gy/fraction). The α/β ratio calcu-
lated by BED formulae was 7.36 Gy. Previous 
study have reported the median α/β ratio of 5.43 
Gy from GBM cells after 2 Gy x-ray exposure 
(41). Increasing the ratio of α/β from 5.43 in R 
group to 7.36 Gy in R/2ME/IUDR/TPT groups 
from GBM cell line U87 seemed to be reasonable, 
because with increasing DSB, repair of this dam-
age hardly occurred (42, 43). In another study, 
the median α/β ratio for temozolomide/radiation 
(TMZ/R) was 9.32 Gy in the GBM-U87 cell line 
(44). Furthermore, the DNA damage was greater 
in the presence of R/ 2ME2/TPT compared with 
R/TPT alone. This could be due to cease of cell 
cycles in G2/M phases and thus prevention of 
tumor growth. That is why in this study, in ad-
dition to TPT we used IUDR and 2ME2 as ra-
diosensitizer agents so that their combined use 
would have an accumulative effect especially in 
fractionated radiotherapy. With this accumulative 
effect, the absorption dose to create damage will 
be increased significantly and treatment of GBM 
could have more success.
Conclusion
These results suggest that R/TPT-treated cells 
increase sensitivity of 2ME2 and IUDR especially 
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when they are used together and may improve the 
therapeutic index for radiation. Our purpose for 
further studies is to make use of TPT with pifithrin 
or inhibitors of p53 as a co-treatment after irradia-
tion with X-6MV to enhance tumor radiosensitiza-
tion to TPT and then evaluate the combined effects 
of these agents on the cells.
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